CTS 2026: What to Expect in Las Vegas

Arshad M. Khanani, MD, previews this year’s Clinical Trials at the Summit meeting, highlighting new clinical trial data, expert panels discussing a variety of topics, and a keynote by the former director of the FDA’s ophthalmic devices division.

By
Arshad M. Khanani, MD, MA, FASRS
June 1, 2026
2 min

Retinal Physician

Overview

CTS 2026 will feature 139 program participants and approximately 90 presentations, including phase 2 and phase 3 trial results. The meeting will also include expert panels and a keynote lecture from a former FDA director.

Background

The Clinical Trials at the Summit (CTS) meeting is a significant event for professionals in the field of ophthalmology, particularly focusing on retinal therapeutics. This year's meeting will showcase new clinical trial data and discussions on emerging topics, reflecting the ongoing advancements in the field.

Data Highlights

No numerical or trial data provided in the source material.

Key Findings

CTS 2026 will take place on June 12 and 13 in Las Vegas, Nevada.
The agenda includes 139 program participants and approximately 90 presentations.
First-time results from phase 2 and phase 3 trials will be presented.
Topics will include artificial intelligence in retinal clinical trials and investment outlook for retinal therapeutics.
The meeting will feature a keynote lecture by Wiley A. Chambers, MD.
Three prestigious awards will be presented during the event.

Clinical Implications

The CTS 2026 meeting will provide healthcare professionals with insights into the latest clinical trial findings and advancements in retinal therapeutics. Engaging discussions and expert panels will enhance understanding of current trends and future directions in the field.

Conclusion

CTS 2026 promises to be an informative event for ophthalmology professionals, highlighting critical advancements and fostering collaboration within the field.